noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Taft Stettinius & Hollister LLP

Sandifer to Moderate Panel at Black Entertainment and Sports Lawyers[...]
Zoomcar Holdings Inc.

Amendment to Tender Offer Statement (Form SC TO-I/A)
Cavco Industries Inc.

Cavco Industries Annouces Building New Manufacturing Facility in El[...]

Healthcare

Personalis Inc.

05/20/2026 | Press release | Distributed by Public on 05/20/2026 14:04

Material Event (Form 8-K)

Item 8.01 Other Events.

On May19, 2026, the Centers for Medicare & Medicaid Services Molecular Diagnostics Program expanded Medicare coverage for Personalis, Inc.'s ultrasensitive NeXT Personal® test to include monitoring treatment response to neoadjuvant therapy (NAT) in patients diagnosed with Stage II-III Triple-Negative Breast Cancer (TNBC) or HER2-positive (HER2+) breast cancer.

Personalis Inc. published this content on May 20, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on May 20, 2026 at 20:04 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]